Top 50 Pharma
Find reports on global pharmaceutical companies. Piribo has indentified the top 50 global companies (by sales) and they have their own categories.
In A-Z order:
Abbott, Actavis, Alcon, Allergan, Amgen, Astellas, AstraZeneca, Barr Pharmaceuticals, Baxter, Bayer, Biogen Idec, Boehringer-Ingelheim, Bristol-Myers Squibb, Chugai, CSL, Daiichi Sankyo, Eisai, Eli Lilly, Forest, Genentech, Genzyme, Gilead Sciences,GlaxoSmithKline Johnson & Johnson, King Pharmaceuticals, Lundbeck, Menarini, Merck , Merck KGaA, Mitsubishi Tanabe, Mundipharma, Novartis, Novo Nordisk, Nycomed, Otsuka, P&G, Pfizer, Ratiopharm, Roche, Sanofi-Aventis, Schering-Plough, Servier, Shire, Solvay, Stada, Takeda,Teva UCB, Watson and Wyeth
Stay up-to-date with new products added to this category »
In A-Z order:
Abbott, Actavis, Alcon, Allergan, Amgen, Astellas, AstraZeneca, Barr Pharmaceuticals, Baxter, Bayer, Biogen Idec, Boehringer-Ingelheim, Bristol-Myers Squibb, Chugai, CSL, Daiichi Sankyo, Eisai, Eli Lilly, Forest, Genentech, Genzyme, Gilead Sciences,GlaxoSmithKline Johnson & Johnson, King Pharmaceuticals, Lundbeck, Menarini, Merck , Merck KGaA, Mitsubishi Tanabe, Mundipharma, Novartis, Novo Nordisk, Nycomed, Otsuka, P&G, Pfizer, Ratiopharm, Roche, Sanofi-Aventis, Schering-Plough, Servier, Shire, Solvay, Stada, Takeda,Teva UCB, Watson and Wyeth
Stay up-to-date with new products added to this category »
| Title | Publication Date | Price |
|---|---|---|
|
Alcon Medical Device Company Intelligence Report |
November 2009 | £295 |
|
Abbott Laboratories: PharmaVitae Profile Healthcare |
September 2009 | £3765 |
|
AstraZeneca plc: PharmaVitae Profile |
September 2009 | £3765 |
|
Bristol-Myers Squibb Co.: PharmaVitae Profile |
September 2009 | £3765 |
|
GlaxoSmithKline Performance, Capabilities, Goals and Strategies in The Worldwide Pharmaceutical Market |
September 2009 | £1255 |
|
Johnson & Johnson Performance, Capabilities, Goals and Strategies in The Worldwide Pharmaceutical Market |
September 2009 | £1255 |
|
AstraZeneca Performance, Capabilities, Goals and Strategies in The Worldwide Pharmaceutical Market |
September 2009 | £1255 |
|
Merck Performance, Capabilities, Goals and Strategies in The Worldwide Pharmaceutical Market |
September 2009 | £1255 |
|
Bristol-Myers Squibb Performance, Capabilities, Goals and Strategies in The Worldwide Pharmaceutical Market |
September 2009 | £1255 |
|
Pfizer Performance, Capabilities, Goals and Strategies in The Worldwide Pharmaceutical Market |
September 2009 | £1255 |
|
Wyeth Performance, Capabilities, Goals and Strategies in The Worldwide Pharmaceutical Market |
September 2009 | £1255 |
|
Sanofi-Aventis Performance, Capabilities, Goals and Strategies in The Worldwide Pharmaceutical Market |
September 2009 | £1255 |
|
Roche Performance, Capabilities, Goals and Strategies in The Worldwide Pharmaceutical Market |
September 2009 | £1255 |
|
Novartis Performance, Capabilities, Goals and Strategies in The Worldwide Pharmaceutical Market |
September 2009 | £1255 |
|
Johnson & Johnson IMS Company Profile |
August 2009 | £510 |
|
BMS & Medarex: a valuable partnership? |
August 2009 | £175 |
|
Merck & Co and Schering-Plough - a marriage of convenience? |
August 2009 | £295 |
|
Roche & Genentech: a model for future biotech deals? |
August 2009 | £175 |
|
Daiichi Sankyo IMS Company Profile |
July 2009 | £510 |
|
Eli Lilly & Co.: PharmaVitae Profile |
July 2009 | £3765 |
|
Merck & Co. Inc: PharmaVitae Profile |
July 2009 | £3765 |
|
Pfizer IMS Company Profile |
July 2009 | £510 |
|
Amgen IMS Company Profile |
July 2009 | £510 |
|
Johnson & Johnson: PharmaVitae Profile Healthcare |
July 2009 | £3765 |
|
Bayer Schering Pharma AG: PharmaVitae Profile |
July 2009 | £3765 |
|
Novartis AG: PharmaVitae Profile |
July 2009 | £3765 |
|
Johnson & Johnson: Pharma Growth Strategy How does the world's 7th largest pharma company plan to grow its pharmaceutical revenues? |
July 2009 | £245 |
|
Amgen Inc.: PharmaVitae Profile Healthcare |
July 2009 | £3765 |
|
Pfizer Inc.: PharmaVitae Profile |
July 2009 | £3765 |
|
Biogen Idec IMS Company Profile |
July 2009 | £510 |
|
Wyeth IMS Company Profile |
February 2009 | £510 |
|
Daiichi Sankyo Co., Ltd: PharmaVitae Profile |
February 2009 | £1990 |
|
Astellas Pharma Inc.: PharmaVitae Profile |
February 2009 | £1990 |
|
Bristol-Myers Squibb IMS Company Profile |
February 2009 | £510 |
|
Wyeth: PharmaVitae Model |
January 2009 | £1990 |
|
Forest Laboratories Inc.: PharmaVitae Model |
January 2009 | £1990 |
|
Eli Lilly & Co.: PharmaVitae Model |
January 2009 | £1990 |
|
Eisai Co. Ltd: PharmaVitae Model |
January 2009 | £1990 |
|
Genentech Inc.: PharmaVitae Model |
January 2009 | £1990 |
|
Genzyme Corporation: PharmaVitae Model |
January 2009 | £1990 |
|
Takeda Pharmaceutical Co. Ltd: PharmaVitae Model |
January 2009 | £1990 |
|
Teva Pharmaceutical Industries Ltd: PharmaVitae Model |
January 2009 | £1990 |
|
Watson Pharmaceuticals Inc.: PharmaVitae Model |
January 2009 | £1990 |
|
Gilead Sciences Inc.: PharmaVitae Model |
January 2009 | £1990 |
|
Daiichi Sankyo Co., Ltd: PharmaVitae Model |
January 2009 | £1990 |
|
Bristol-Myers Squibb Co.: PharmaVitae Model |
January 2009 | £1990 |
|
Amgen Inc.: PharmaVitae Model |
January 2009 | £1990 |
|
Allergan Inc.: PharmaVitae Model |
January 2009 | £1990 |
|
Alcon Inc.: PharmaVitae Model |
January 2009 | £1990 |
|
Abbott Laboratories: PharmaVitae Model |
January 2009 | £1990 |
|
Astellas Pharma Inc.: PharmaVitae Model |
January 2009 | £1990 |
|
AstraZeneca plc: PharmaVitae Model |
January 2009 | £1990 |
|
Boehringer Ingelhgeim GmbH: PharmaVitae Model |
January 2009 | £1990 |
|
Biogen Idec Inc.: PharmaVitae Model |
January 2009 | £1990 |
|
Bayer Schering Pharma AG: PharmaVitae Model |
January 2009 | £1990 |
|
Solvay S.A.: PharmaVitae Model |
January 2009 | £1990 |
|
Chugai Pharmaceutical Co. Ltd: PharmaVitae Model |
January 2009 | £1990 |
|
Novartis AG: PharmaVitae Model |
January 2009 | £1990 |
|
Mitsubishi Tanabe Pharma Corporation: PharmaVitae Model |
January 2009 | £1990 |
|
Merck KGaA: PharmaVitae Model |
January 2009 | £1990 |
|
Novo Nordisk A/S: PharmaVitae Model |
January 2009 | £1990 |
|
Pfizer Inc.: PharmaVitae Model |
January 2009 | £1990 |
|
Schering-Plough Corporation: PharmaVitae Model |
January 2009 | £1990 |
|
Sanofi-Aventis: PharmaVitae Model |
January 2009 | £1990 |
|
Shire plc: PharmaVitae Model |
January 2009 | £1990 |
|
Shionogi & Co. Ltd: PharmaVitae Model |
January 2009 | £1990 |
|
Les Laboratoires Servier: PharmaVitae Model |
January 2009 | £1990 |
|
Johnson & Johnson: PharmaVitae Model |
January 2009 | £1990 |
|
Merck & Co. Inc: PharmaVitae Model |
January 2009 | £1990 |
|
King Pharmaceuticals Inc.: PharmaVitae Model |
January 2009 | £1990 |
|
Zimmer Medical Device Company Intelligence Report |
December 2008 | £395 |
|
ScientiaVision Competitor Close-up: Merck & Company, Inc. |
December 2008 | £525 |
|
Understanding the Global Pharmaceutical Market |
November 2008 | £395 |
|
Boehringer Ingelheim IMS Company Profile |
November 2008 | £510 |
|
Lundbeck IMS Company Profile |
November 2008 | £510 |
|
Forest Laboratories Inc.: PharmaVitae Profile |
November 2008 | £1990 |
|
Shire plc: PharmaVitae Profile |
November 2008 | £1990 |
|
Boehringer Ingelheim Pipeline ,Products ,Performance ,Potential |
November 2008 | £595 |
|
Slentrol Case Study: Using Integrated PR Tactics to Support a Product Launch |
October 2008 | £665 |
|
Nexium Case Study: Using Public Relations to Reach Diverse Patient Populations and Build Bridges Between Product Generations |
October 2008 | £995 |
|
King Pharmaceuticals IMS Company Profile |
October 2008 | £510 |
|
Bayer Pipeline, Products ,Performance ,Potential |
September 2008 | £595 |
|
Merck KGaA Pipeline ,Products ,Performance ,Potential |
September 2008 | £595 |
|
Pfizer Market Outlook for a Global Leader, 2008-2013 |
August 2008 | £1499 |
|
Byetta Case Study Using Medical Education as a Springboard for Product Launch |
August 2008 | £2905 |
|
Schering-Plough Pipeline ,Products ,Performance ,Potential |
August 2008 | £595 |
|
Eisai |
July 2008 | £510 |
|
Boehringer Ingelheim |
July 2008 | £510 |
|
Shire |
July 2008 | £510 |
|
Daiichi Sankyo |
July 2008 | £510 |
|
Exubera Case Study Misjudging The Market |
July 2008 | £1760 |
|
Pfizer IMS Company Profile |
July 2008 | £510 |
|
Flomax Case Study Evolving Disease State Awareness to Succeed with New Method of Action |
July 2008 | £2110 |
|
Astellas |
July 2008 | £510 |
|
Schering-Plough Corporation PharmaVitae Profile |
July 2008 | £1980 |
|
AstraZeneca Plc PharmaVitae Profile |
July 2008 | £1980 |
|
Johnson & Johnson PharmaVitae Profile |
July 2008 | £1980 |
|
Bayer Schering Pharma Ag PharmaVitae Profile |
July 2008 | £1980 |
|
Wyeth PharmaVitae Profile |
July 2008 | £1980 |
|
AstraZeneca Pharmaceuticals, Company Profile and Healthcare |
June 2008 | £595 |
|
Gilead Sciences IMS Company Profile |
June 2008 | £510 |
|
Pfizer Pipeline ,Products ,Performance ,Potential |
June 2008 | £595 |
|
Cymbalta Case Study Successfully Entering a Crowded Market with a New Mechanism of Action |
June 2008 | £3170 |
|
Allergan IMS Company Profile |
June 2008 | £510 |
|
Mylan IMS Company Profile |
June 2008 | £510 |
|
Shire: Pipeline | Products | Performance | Potential |
May 2008 | £595 |
|
Chugai IMS Company Profile |
May 2008 | £510 |
|
Solvay IMS Company Profile |
May 2008 | £510 |
|
UCB IMS Company Profile |
May 2008 | £510 |
|
Bristol-Myers Squibb Pipeline, Products, Performance, Potential |
February 2008 | £595 |
|
Allergan: Pipeline , Products , Performance , Potential |
February 2008 | £595 |
|
Johnson & Johnson: Strategic Analysis Profile |
February 2008 | £520 |
|
SERVIER -Company Report |
February 2008 | £250 |
|
Boehringer Ingelheim Gmbh Pharmavitae Profile |
December 2007 | £1990 |
|
Shire Plc Pharmavitae Profile |
December 2007 | £1980 |
|
Biogen Idec Inc. Pharmavitae Profile |
December 2007 | £1980 |
|
Bristol-Myers Squibb Co. Pharmavitae Profile |
December 2007 | £1980 |
|
Eisai Co., Ltd Pharmavitae Profile |
December 2007 | £1990 |
|
Astrazeneca Plc (Incl. Medimmune Inc.) Pharmavitae Profile |
December 2007 | £1990 |
|
Astellas Pharma Inc. Pharmavitae Profile |
December 2007 | £1990 |
|
Abbott Laboratories Pharmavitae Profile |
December 2007 | £1980 |
|
Amgen Inc. Pharmavitae Profile |
December 2007 | £1980 |
|
Eli Lilly & Co. Pharmavitae Profile |
December 2007 | £1980 |
|
Forest Laboratories Inc. Pharmavitae Profile |
December 2007 | £1990 |
|
Pfizer Inc. Pharmavitae Profile |
December 2007 | £1980 |
|
Takeda Pharmaceutical Co., Ltd Pharmavitae Profile |
December 2007 | £1990 |
|
Menarini Pharmavitae Profile |
December 2007 | £1980 |
|
Merck & Co., Inc. Pharmavitae Profile |
December 2007 | £1980 |
|
H. Lundbeck A/S Pharmavitae Profile |
December 2007 | £1980 |
|
Gilead Sciences Inc. Pharmavitae Profile |
December 2007 | £1990 |
|
Ono: Pipeline, Products, Performance, Potential |
November 2007 | £595 |
|
Astellas Pharma: Pipeline, Products, Performance, Potential |
November 2007 | £595 |
|
Roche: Pipeline, Products, Performance, Potential |
November 2007 | £595 |
|
AstraZeneca: Pipeline, Products, Performance, Potential |
November 2007 | £595 |
|
Takeda: Pipeline, Products, Performance, Potential |
November 2007 | £595 |
|
Biosimilars Benchmarking the key players PharmaVitae Profile |
November 2007 | £1980 |
|
Stakeholder Opinions Gynecological Cancers Niche opportunities in advanced disease |
November 2007 | £1980 |
|
Stada IMS Company Profile |
November 2007 | £249 |
|
Forest IMS Company Profile |
November 2007 | £249 |
|
Mitsubishi Pharma: Pipeline, Products, Performance, Potential |
October 2007 | £595 |
|
Genentech: PharmaVitae Profile Pharmavitae Profile |
October 2007 | £1980 |
|
Stakeholder Opinions Melanoma Lucrative commercial opportunities persist |
October 2007 | £1980 |
|
Roche: Prospects to 2010 Pipeline, Products,Performance,Potential |
September 2007 | £595 |
|
Sanofi-aventis Pipeline, Products,Performance,Potential |
September 2007 | £249 |
|
Pfizer Prospects to 2010 Pipeline, Products,Performance,Potential |
September 2007 | £595 |
|
Watson Pharmavitae Generics Profile |
September 2007 | £1325 |
|
Otsuka Prospects to 2010 |
August 2007 | £249 |
|
Wyeth Prospects to 2010 Performance, Products, Pipeline and Potential |
July 2007 | £595 |
|
Johnson & Johnson Prospects to 2010 |
June 2007 | £595 |
|
Novo Nordisk Pharmaceutical Company Intelligence Report Prospects to 2010 |
May 2007 | £595 |
|
Baxter IMS Company Profile |
May 2007 | £249 |
|
Bayer Company Profile |
May 2007 | £249 |
|
Biogen Idec: PharmaVitae Profile PharmaVitae Profile |
March 2007 | £1980 |
|
Daiichi Sankyo: PharmaVitae Profile PharmaVitae Profile |
January 2007 | £1980 |
|
Novartis PharmaVitae Profile |
January 2007 | £1980 |
|
Schering AG Prospects to 2010 |
November 2006 | £895 |
|
Lundbeck: PharmaVitae Profile |
November 2006 | £3000 |
|
Eisai: PharmaVitae Profile |
November 2006 | £3000 |
|
Merck & Co: PharmaVitae Profile |
November 2006 | £1980 |
|
Actavis IMS Company Profile |
September 2006 | £249 |
|
Forest IMS Company Profile |
September 2006 | £249 |
|
Spotlight Report Series: Deal Making Spotlight on GlaxoSmithKline |
April 2006 | £350 |
|
Spotlight Report Series: Deal Making Spotlight on Johnson & Johnson |
April 2006 | £350 |
|
Spotlight Report Series: Deal Making Spotlight on Pfizer |
April 2006 | £350 |
|
Spotlight Report Series: Deal Making Spotlight on Sanofi-Aventis |
April 2006 | £350 |
|
Spotlight Report Series: Deal Making Spotlight on Novartis |
April 2006 | £350 |
|
Johnson & Johnson Inc |
February 2006 | £195 |
|
Bristol-Myers Squibb Company Deals Partneringdesk briefing |
July 2005 | £215 |
|
Amgen Inc Deals Partneringdesk briefing |
July 2005 | £215 |
|
Schering-Plough Corporation Deals Partneringdesk briefing |
July 2005 | £215 |
|
AstraZeneca Deals Partneringdesk briefing |
July 2005 | £215 |
|
Eli Lilly and Company Deals Partneringdesk briefing |
July 2005 | £215 |
|
Merck & Co Inc Deals Partneringdesk briefing |
July 2005 | £215 |
|
Pfizer Inc Deals Partneringdesk briefing |
July 2005 | £215 |
|
Abbott Laboratories Deals Partneringdesk briefing |
July 2005 | £215 |
|
Boehringer Ingelheim GmbH Deals Partneringdesk briefing |
July 2005 | £215 |
|
H Lundbeck Deals Partneringdesk briefing |
July 2005 | £215 |
|
Shire Pharmaceuticals Group PLC Deals Partneringdesk briefing |
July 2005 | £215 |
|
Daiichi Pharmaceutical Co Ltd Deals Partneringdesk briefing |
July 2005 | £215 |
|
Bayer AG Deals Partneringdesk briefing |
July 2005 | £215 |
|
Johnson & Johnson Deals Partneringdesk briefing |
July 2005 | £215 |
|
Eisai Co Ltd Deals Partneringdesk briefing |
July 2005 | £215 |
|
Astellas Pharma Inc Deals Briefing Partneringdesk |
June 2005 | £215 |
|
Merck Druggernaut; The The Inside Story of a Pharmaceutical Giant |
March 2005 | £11.99 |
|
Abbott Laboratories Strategic Analysis Profile |
November 1999 | £520 |
|
Alcon Inc. Strategic Analysis Profile |
November 1999 | £520 |
